ERBB2 and gastric cancer: While ERBB2/HER2 amplification and overexpression have been extensively studied in breast and gastric cancers, where they are associated with poor prognosis and aggressive tumor biology,20,21 their prevalence, prognostic significance, and therapeutic implications in other tumor types remain less well-defined.